Zobrazeno 1 - 10
of 142
pro vyhledávání: '"Shrujal S Baxi"'
Autor:
Michael A Postow, Maha Mamoor, Jessica A Lavery, Shrujal S Baxi, Niloufer Khan, Jun J Mao, Lauren J Rogak, Robert Sidlow, Bridgette Thom, Jedd A Wolchok, Deborah Korenstein
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 1 (2020)
Background Immune checkpoint inhibitors (CIs) have revolutionized treatment of advanced melanoma, leading to an emerging population of long-term survivors. Survivors’ quality of life (QOL) and symptom burden are poorly understood. We set out to eva
Externí odkaz:
https://doaj.org/article/5312ac9aae874a10a0c06330b4c02363
Autor:
Vatche, Tchekmedyian, Lara, Dunn, Eric, Sherman, Shrujal S, Baxi, Ravinder K, Grewal, Steven M, Larson, Keith S, Pentlow, Sofia, Haque, R Michael, Tuttle, Mona M, Sabra, Stephanie, Fish, Laura, Boucai, Jamie, Walters, Ronald A, Ghossein, Venkatraman E, Seshan, Jeffrey A, Knauf, David G, Pfister, James A, Fagin, Alan L, Ho
Publikováno v:
Thyroid
BACKGROUND: Oncogenic activation of mitogen-activated protein kinase (MAPK) signaling is associated with radioiodine refractory (RAIR) thyroid cancer. Preclinical models suggest that activation of the receptor tyrosine kinase erbB-3 (HER3) mitigates
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::c9f46ba30ee567420adda24c8ee14244
https://pubmed.ncbi.nlm.nih.gov/35045748
https://pubmed.ncbi.nlm.nih.gov/35045748
Autor:
Vatche Tchekmedyian, Lara Dunn, Eric Sherman, Shrujal S. Baxi, Ravinder K. Grewal, Steven M. Larson, Keith S. Pentlow, Sofia Haque, R. Michael Tuttle, Mona M. Sabra, Stephanie Fish, Laura Boucai, Jamie Walters, Ronald A. Ghossein, Venkatraman E. Seshan, Jeffrey A. Knauf, David G. Pfister, James A. Fagin, Alan L. Ho
Publikováno v:
Thyroid. 32:273-282
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::dad176b1cb35f557bbbd911ed137bcf1
https://doi.org/10.1089/thy.2021.0565
https://doi.org/10.1089/thy.2021.0565
Autor:
Nicholas J Robert, Marley Boyd, Shrujal S. Baxi, Aaron B Cohen, Yanina Natanzon, Olga Tymejczyk, Mark Stewart, Laura Lasiter, Elizabeth Garrett-Mayer, Donna R. Rivera, Jeff Allen, Monika A Izano, Eric Hansen, Mackenzie Small, Jennifer B. Christian, Andrew J. Belli, Joseph Wagner, Janet L. Espirito, Connor Sweetnam
Publikováno v:
Clinical Pharmacology & Therapeutics. 111:444-454
In prior work, Friends of Cancer Research convened multiple data partners to establish standardized definitions for oncology real-world end points derived from electronic health records (EHRs) and claims data. Here, we assessed the performance of rea
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ebac8e31166fd8a9e91525c60d34544a
https://doi.org/10.1002/cpt.2443
https://doi.org/10.1002/cpt.2443
Autor:
Zhiwen Liu, Diana Chirovsky, Shrujal S. Baxi, Karthik Ramakrishnan, Sam Joo, Sheenu Chandwani
Publikováno v:
Future Oncology. 17:3037-3050
Aim: We report real-world time on treatment (rwToT) with immuno-oncology (I-O) and other systemic therapies in second-line recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) previously treated with platinum therapies. Materials
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c4625fad336873c8632b2a215f56609e
https://doi.org/10.2217/fon-2021-0360
https://doi.org/10.2217/fon-2021-0360
Autor:
Eric J. Sherman, Jahan Aghalar, Nancy Y. Lee, Sean McBride, Robert J. Young, Robert A. Lefkowitz, Zhigang Zhang, C. Jillian Tsai, Shrujal S. Baxi, Lara Dunn, Loren S. Michel, Alan L. Ho, David G. Pfister, Juliana Eng, D. Spielsinger, Jessica Flynn, Nadeem Riaz, Daniel C. McFarland, Wanqing Iris Zhi
Publikováno v:
Journal of Clinical Oncology. 39:30-37
PURPOSE The objective response rate (ORR) for single-agent anti–programmed death receptor 1 (anti–PD-1) therapy is modest in patients with metastatic or recurrent head and neck squamous cell carcinoma (HNSCC). We aimed to test whether radiotherap
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::52871671e43fcf5e0e561b9e225d1106
https://doi.org/10.1200/jco.20.00290
https://doi.org/10.1200/jco.20.00290
Autor:
Maha Mamoor, Robert Sidlow, Niloufer Khan, Jessica A. Lavery, Lauren J. Rogak, Bridgette Thom, Deborah Korenstein, Shrujal S. Baxi
Publikováno v:
J Psychosoc Oncol
PURPOSE: To measure financial toxicity and explore its association with quality of life (QOL) in an emerging population of survivors: advanced melanoma patients treated with immunotherapy. DESIGN: Cross-sectional survey and medical record review. SAM
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2d5e9f6a64523ad66a5a5b291e8ebd3e
https://doi.org/10.1080/07347332.2020.1836547
https://doi.org/10.1080/07347332.2020.1836547
Autor:
Elad Sharon, Andrew N. Freedman, Aracelis Z. Torres, Susan Spillane, David Lenis, Angela B. Mariotto, Shrujal S. Baxi
Publikováno v:
The Oncologist
Background Real‐world data enables evaluation of immune checkpoint inhibitor (ICI) use in advanced melanoma management. We examined characteristics and outcomes of ICI‐treated patients with advanced melanoma and organ dysfunction (baseline and em
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c1a68af8d048529c31e25268e7459967
https://doi.org/10.1634/theoncologist.2020-0055
https://doi.org/10.1634/theoncologist.2020-0055
Autor:
Nora Katabi, Matthew G. Fury, Lara Dunn, Shrujal S. Baxi, Loren S. Michel, Sofia Haque, Richard J. Wong, Nadeem Riaz, Sean McBride, David G. Pfister, Han Xiao, Alan L. Ho, Eric J. Sherman, Nancy Y. Lee
Publikováno v:
Int J Radiat Oncol Biol Phys
Purpose Activation of the PI3K/mTOR signaling pathway is common in head and neck squamous cell carcinoma (HNSCC). BYL719 is an α-specific PI3K inhibitor that is synergistic and efficacious when combined with cetuximab, a Food and Drug Administration
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8294f6339e56348d7adc6207e43a0afe
https://doi.org/10.1016/j.ijrobp.2019.09.050
https://doi.org/10.1016/j.ijrobp.2019.09.050
Autor:
W. Katherine Tan, Brian D. Segal, Melissa D. Curtis, Shrujal S. Baxi, William B. Capra, Elizabeth Garrett-Mayer, Brian P. Hobbs, David S. Hong, Rebecca A. Hubbard, Jiawen Zhu, Somnath Sarkar, Meghna Samant
Publikováno v:
Contemporary Clinical Trials Communications. 30:101000
Randomized controlled trials (RCTs) are the gold standard for assessing drug safety and efficacy. However, RCTs have some drawbacks which have led to the use of single-arm studies to make certain internal drug development and regulatory decisions, pa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3061afdffeb6c9a15947c1e082b21c07
https://doi.org/10.1016/j.conctc.2022.101000
https://doi.org/10.1016/j.conctc.2022.101000